A Retrospective Database Study of Liraglutide Persistence Associated with Glycemic and Body Weight Control in Patients with Type 2 Diabetes

Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
Cheli Melzer-CohenAvraham Karasik

Abstract

In both randomized controlled trials and real-world studies, liraglutide has demonstrated glycemic and body weight benefits in patients with type 2 diabetes. However, persistence with diabetes medication can be challenging. This study compared glycated hemoglobin (HbA1c) and other outcomes in patients with type 2 diabetes who continued treatment with liraglutide for over 12 months with those who discontinued treatment earlier, in a real-life setting. This is a retrospective study of adult patients with type 2 diabetes from Maccabi Healthcare Services in Israel, who initiated treatment with liraglutide from 2010 to 2015. Mean HbA1c and body weight change from initiation to after 24 months was compared between patients who received liraglutide for at least 12 months ("continuers") and those who discontinued within the first year ("discontinuers"). Adjustment for HbA1c, body weight, and other potentially confounding factors was performed using 1:1 propensity score matching. The 3580 patients comprised 2695 continuers and 885 discontinuers; 882 patients per group were matched. A significant (p < 0.001) reduction in HbA1c (- 0.80% vs - 0.32%) was seen in continuers compared with discontinuers, despite higher insulin usage (70.2% vs ...Continue Reading

References

Feb 5, 2004·European Journal of Epidemiology·Gabriel ChodickEhud Kookia
Aug 23, 2005·Diabetes Research and Clinical Practice·Anthony D HeymannEhud Kokia
May 15, 2007·Gastroenterology·Laurie L Baggio, Daniel J Drucker
Aug 19, 2009·Diabetologia·D Russell-JonesUNKNOWN Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group
Oct 26, 2012·Expert Opinion on Drug Metabolism & Toxicology·Maria J JespersenMikkel Christensen
Aug 31, 2013·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Luis-Emilio García-PérezDomingo Orozco-Beltrán
Mar 26, 2014·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Anthony HeymannAvraham Karasik
Dec 24, 2015·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Thomas WilkeUlf Maywald
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Jun 29, 2016·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Amrita OstawalWeiwei Xu
Sep 17, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN SUSTAIN-6 Investigators
Jan 11, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Victoria DivinoKirsi Norrbacka
Oct 17, 2017·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Mirko V SikiricaVictoria Higgins
May 31, 2018·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J Garber, UNKNOWN 2018 AACE T2D Algorithm Authors

❮ Previous
Next ❯

Software Mentioned

SAS

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.